Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The secreted Bv8 protein has been recently characterized as a regulator of myeloid cell mobilization and a neutrophil-derived mediator of tumor angiogenesis in several xenografts, but its role in tumor progression in an endogenous setting was unknown. The rat insulin promoter (RIP)–T-antigen (Tag) is a well characterized transgenic mouse model of multistage pancreatic β-cell tumorigenesis. Also, the role of neutrophils in RIP-Tag angiogenic switching, as assessed by systemic ablation using anti-Gr1 antibodies at different stages of tumor progression, has been recently described. Here, we show that early treatment of RIP-Tag mice with anti-Bv8 antibodies resulted in a significant reduction in the number of angiogenic islets relative to control antibody-treated mice, implicating Bv8 in the angiogenic switch during neoplasia. Histological analysis showed a significant reduction in vascular surface areas in hyperplastic and angiogenic lesions in pancreatic islets from anti-Bv8-treated mice. Anti-Bv8 treatment also inhibited the mobilization and homing of CD11b+Gr1+ cells to the peripheral blood and the emerging neoplastic lesions. However, anti-Bv8 treatment had no effect on tumor vascularization or burden when initiated at later stages of tumor progression. The stage-dependent efficacy of anti-Bv8 treatment appears remarkably similar to that reported after neutrophil ablation, suggesting that Bv8 is an important mediator of neutrophil-dependent angiogenesis in this transgenic model. In summary, our studies verify a role for Bv8 in the mobilization and recruitment of myeloid cells and in the induction of tumor angiogenesis in the early stages of neoplastic progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“Vascular endothelial growth factor (VEGF)-A is one of the most important regulators of physiological and/or pathological angiogenesis (2).”
BackgroundSelf-citationPatterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 3×
“I t is now well established that angiogenesis plays a crucial role in tumor progression (1).”
BackgroundSelf-citationCasanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · cited 1×
“Discussion Previous studies have suggested a role for myeloid cells in tumor growth and angiogenesis (30, 31).”
BackgroundEffects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · cited 3×
“RIP1-Tag2 or RIP-Tag mice have been described (9).”
BackgroundMethodInfluentialNozawa, H., Chiu, C., & Hanahan, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601807103 · Cited by 923
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 1×
“We recently demonstrated that CD11b Gr1 myeloid cells are a population mediating refractoriness to anti-VEGF treatment in several tumor models (32).”
BackgroundSelf-citationProkineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus
Cheng, M. Y., Bullock, C. M., Li, C., Lee, A. G., Bermak, J. C., Belluzzi, J., Weaver, D. R., Leslie, F. M., & Zhou, Q.-Y. (2002) · Nature · doi:10.1038/417405a · Cited by 715 · cited 1×
“More recently, several important functions have been associated with Bv8 receptor signaling, including regulation of circadian rhythms (22), olfactory bulb neurogenesis, and survival of GnRH neurons (23, 24).”
BackgroundBv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Self-citationIdentification of an angiogenic mitogen selective for endocrine gland endothelium
LeCouter, J., Kowalski, J., Foster, J., Hass, P., Zhang, Z., Dillard-Telm, L., Frantz, G., Rangell, L., DeGuzman, L., Keller, G.-A., et al. (2001) · Nature · doi:10.1038/35091000 · Cited by 555
Self-citationKallmann Syndrome: Mutations in the Genes Encoding Prokineticin-2 and Prokineticin Receptor-2
Dodé, C., Teixeira, L., Levilliers, J., Fouveaut, C., Bouchard, P., Kottler, M.-L., Lespinasse, J., Lienhardt-Roussie, A., Mathieu, M., Moerman, A., et al. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020175 · Cited by 457
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Self-citationLiang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Self-citationDependence of Olfactory Bulb Neurogenesis on Prokineticin 2 Signaling
Ng, K. L., Li, J.-D., Cheng, M. Y., Leslie, F. M., Lee, A. G., & Zhou, Q.-Y. (2005) · Science · doi:10.1126/science.1112103 · Cited by 331
Lin, D. C.-H., Bullock, C. M., Ehlert, F. J., Chen, J.-L., Tian, H., & Zhou, Q.-Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202139200 · Cited by 313
Matsumoto, S.-I., Yamazaki, C., Masumoto, K.-H., Nagano, M., Naito, M., Soga, T., Hiyama, H., Matsumoto, M., Takasaki, J., Kamohara, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508881103 · Cited by 281 · cited 1×
“More recently, several important functions have been associated with Bv8 receptor signaling, including regulation of circadian rhythms (22), olfactory bulb neurogenesis, and survival of GnRH neurons (23, 24).”
BackgroundLi, M., Bullock, C. M., Knauer, D. J., Ehlert, F. J., & Zhou, Q. Y. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.692 · Cited by 269
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238
Self-citationLeCouter, J., Zlot, C., Tejada, M., Peale, F., & Ferrara, N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407697101 · Cited by 219
Self-citationMasuda, Y., Takatsu, Y., Terao, Y., Kumano, S., Ishibashi, Y., Suenaga, M., Abe, M., Fukusumi, S., Watanabe, T., Shintani, Y., et al. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00239-5 · Cited by 213
LeCouter, J., Lin, R., Tejada, M., Frantz, G., Peale, F., Hillan, K. J., & Ferrara, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337667100 · Cited by 201
Self-citationBv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats
Mollay, C., Wechselberger, C., Mignogna, G., Negri, L., Melchiorri, P., Barra, D., & Kreil, G. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00229-0 · Cited by 188
The AVIT protein family: Secreted cysteine-rich vertebrate proteins with diverse functions
Kaser-Eichberger, A., Winklmayr, M., Lepperdinger, G., & Kreil, G. (2003) · EMBO Reports · doi:10.1038/sj.embor.embor830 · Cited by 149
LeCouter, J. E., Lin, R., & Ferrara, N. (2002) · Nature Medicine · doi:10.1038/nm0902-913 · Cited by 119
Self-citationPK1/EG-VEGF induces monocyte differentiation and activation
Dorsch, M., Qiu, Y., Soler, D. F., Frank, N., Duong, T., Goodearl, A. D. J., O'Neil, S., Lora, J. M., & Fraser, C. C. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0205061 · Cited by 114
Lin, R., LeCouter, J., Kowalski, J., & Ferrara, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110594200 · Cited by 110
Self-citationMIT1, a black mamba toxin with a new and highly potent activity on intestinal contraction
Schweitz, H., Pacaud, P., Diochot, S., Moinier, D., & Lazdunski, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01459-3 · Cited by 96
Boisbouvier, J., Albrand, J. P., Blackledge, M. J., Jaquinod, M., Schweitz, H., Lazdunski, M., & Marion, D. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2057 · Cited by 76
Antiangiogenic Therapy for Cancer: An Update
Shojaei, F., & Ferrara, N. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31815a7b69 · Cited by 72
Self-citationLeCouter, J. E., Lin, R., Frantz, G. D., Zhang, Z., Hillan, K. J., & Ferrara, N. (2003) · Endocrinology · doi:10.1210/en.2002-0146 · Cited by 58
Self-citation
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Neutrophils in the activation and regulation of innate and adaptive immunity
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3024 · Cited by 3,027
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Metadata
- Authors
- Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-02-19
- Volume
- 105
- Issue
- 7
- Pages
- 2640-2645
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2001037898
- Cited by
- 334
- References
- 35
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.